News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

UCLA Researchers Develop Lens-Free Smartphone Microscope, Pathologists May Be Able to Take the Clinical Pathology Laboratory Just About Anywhere

In a trial, the lens-free microscope invention from the UCLA California Nano Systems Institute enabled a board-certified pathologist to detect cancers and other cellular abnormalities at 99% accuracy

One of our favorite innovators is at it again, this time with a device that could eventually allow pathologists to use a device coupled with a smartphone to view cancer and other abnormalities at the cellular level.

At UCLA, Professor Aydogan Ozcan, Ph.D. is already well known for having invented attachments that use a smartphone’s camera to create a tiny, lens-free microscope. Now Ozcan, who is the Chancellor’s Professor of Electrical Engineering and Bioengineering at the UCLA Henry Samueli School of Engineering and Applied Science, has created an inexpensive smartphone device that produces holographic images of tissue samples that allow pathologists to view cancer and other abnormalities at the cellular level, according to a December 17, 2014, Science Translational Medicine (STM) article. (more…)

In the UK, Pathologists Are Watching Phase II of a Clinical Trial for a Breathalyzer System That Uses Only a Breath Specimen to Diagnose Lung Cancer

If the clinical study validates this patient-friendly, non-invasive approach to diagnosing lung cancer, it could eventually mean fewer referrals of tissue biopsies to medical laboratories

For almost a decade, pathologists have seen a regular stream of news stories about technologies that utilize a sample of human breath to diagnose a disease or health condition. Now comes news that just such a diagnostic test for lung cancer is beginning clinical trials in the United Kingdom.

The clinical trials will evaluate breathalyzer technology developed by Engineer Billy Boyle, M.S., Co-founder and President of Operations at Cambridge-based Owlstone Ltd.. The clinical trials of this new breathalyzer technology to detect lung cancer are taking place at two National Health Service (NHS) hospitals: University Hospitals of Leicester and Cambridge’s Papworth Hospital in the United Kingdom.

The reason why so much research is happening in this field will be familiar to clinical laboratory managers and pathologists. Use of volatile organic compound (VOC) biomarkers in breath to diagnose disease is an ideal concept because it is convenient, non-invasive, and well tolerated by patients. However, until the start of this clinical study, researchers have explored the potential of this diagnostic approach for some time, but with limited success. (more…)

Researcher at Imperial College London Develops Smart Knife that Allows Surgeons to Detect Cancer In Situ and Without Pathologist Review

Pathologists take note: In one clinical study, diagnostic results produced by a prototype “smart knife” matched postoperative histological diagnosis in 100% of cases

Will a smart knife used in cancer surgery eventually replace the need for a skilled pathologist to diagnose tissue collected during such surgeries?

That’s a question that may be asked in the future if an invention developed at Imperial College London makes it through clinical trials and is accepted for use in patient care. Researchers at Imperial College developed a surgical knife that allows doctors to discern cancer in real-time during surgery—and without consulting with a pathologist.

This invention, dubbed an intelligent knife or iKnife, could be a significant development for clinical laboratory professionals and pathologists if primary research is validated in planned clinical trials.

Pathologists know that when a patient is suspected of having cancer, the current protocols for frozen specimens call for tissue specimens to be sent from the surgical suite to the medical laboratory for analysis. This step may take 20 to 30 minutes.

Meanwhile, the study points out, the patient remains in surgery and under anesthesia. The surgeon waits to learn from the pathologist whether more tissue may need to be removed to ensure that no malignant cells remain in the patient. (more…)

UnitedHealthcare Pushes Back Start Date for Making Claims-Payment Decisions Based on its Florida Pilot Management Program for Medical Laboratory Tests

Health plan sets no new date for BeaconLBS claims-payment decisions but promises 30-days’ notice before making decisions on claims payment

Physicians, pathologists, and clinical laboratories in Florida got a late Christmas present last week. UnitedHealthcare (UHC) (NYSE:UNH) postponed the date when its medical laboratory benefit-management pilot program in Florida, administered by BeaconLBS, would affect claims payments.

This was welcome news, because, beginning January 1, if physicians serving UHC patients had failed to use the BeaconLBS system to obtain pre-notification or pre-authorization for 82 medical laboratory tests, the physicians or labs performing the tests would not be paid by UHC—nor could clinical labs and pathology groups in the UHC provider network bill patients for these tests. (more…)

University of Washington Scientists and Engineers Create Credit-Card-Sized, Microfluidic Device Capable of Diagnosing Pancreatic Cancer in Minutes

The device automates the process used by pathology labs to process biopsy specimens and could be applied to automate other scientific processes

Hoping to speed up the processing of human biopsies to reduce the time required to diagnose cancers, two undergraduate engineering students at the University of Washington (UW) have developed a cheap, miniaturized device that could one day be used in anatomic pathology laboratories.

The protype is a low-cost, credit-card-sized device that automates the processing of human tissue biopsies using fluid transport. The device could help pathologists diagnose pancreatic cancer earlier and faster, to hopefully treat patients before it progresses to a deadly stage, according to a UW press release.

Unlike cancers that can be diagnosed early with fine needle biopsy, such as breast cancer, pancreatic cancer is one of the deadliest forms of cancers. It kills 94% of victims within five years because diagnosis usually is too late to effectively treat the disease. (more…)

;